Triple
T21154201
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | SIGA Technologies |
E521269
|
entity |
| Predicate | hasRegulatoryApproval |
P24602
|
FINISHED |
| Object | European Medicines Agency |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: European Medicines Agency | Statement: [SIGA Technologies, hasRegulatoryApproval, European Medicines Agency]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: European Medicines Agency Context triple: [SIGA Technologies, hasRegulatoryApproval, European Medicines Agency]
-
A.
European Medicines Agency
chosen
The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
-
B.
European Union Drugs Agency
The European Union Drugs Agency is the EU’s central body responsible for providing scientific analysis, monitoring, and policy support on drugs and drug addiction across member states.
-
C.
European medicines regulatory authorities
European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
-
D.
Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use is the European Medicines Agency’s expert body responsible for evaluating and providing scientific opinions on the safety, quality, and efficacy of medicines for human use in the European Union.
-
E.
Committee for Proprietary Medicinal Products
The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b50d1ea481909c07e63c3ead9316 |
completed | April 16, 2026, 10:08 a.m. |
| NER | Named-entity recognition | batch_69e7252a48788190bfdfe811fc6cfc06 |
completed | April 21, 2026, 7:20 a.m. |
Created at: April 16, 2026, 2:58 p.m.